Who owns Aldeyra Therapeutics, Inc. (ALDX)? Elite investor 13F holders
2 tracked elite investors reported holding Aldeyra Therapeutics, Inc as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | ALDEYRA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 4132920.00 USD | 1940338.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | ALDEYRA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 1878660.00 USD | 882000.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.